Introduction
Hepatocellular carcinoma (HCC) is among the commonest cancers worldwide, with an increasing annual incidence in many countries (Bosch, 1997; El-Serag and Mason, 1999) . In more than 80% of cases, HCC development has been linked to chronic infection with hepatitis B and C viruses. Other risk factors include alcohol-related cirrhosis and dietary exposure to a¯atoxin B1 (Schafer and Sorell, 1999) . Allelotype studies of human HCC have demonstrated recurrent loss of heterozygosity (LOH) at multiple chromosome loci, mostly on chromosome arms 1p, 4q, 6q, 8p, 9p, 13q, 16p, 16q and 17p (Boige et al., 1997; Nagai et al., 1997) . Comparative genomic hybridization (CGH) con®rmed these losses and revealed frequent chromosome gains involving 1q, 8q, 6p and 17q arms (Marchio et al., 1997) . Among known tumor suppressor genes (TSGs), LOH has been reported for TP53 at 17p13, RB at 13q14, axin at 16p13 and mannose-6-phosphate/IGF-II receptor at 6q27 (De Souza et al., 1995; Murakami et al., 1991; Satoh et al., 2000) . TSGs localized in other frequently deleted regions remain presently unknown. Few oncogenes, namely c-Myc and b-catenin, are known to be activated in HCC (reviewed in Buendia, 2000) . Recent studies support the notion that distinct pathways might be dierentially activated in HCCs of various etiological origins (Laurent-Puig et al., 2001) . A hot-spot mutation at codon 249 of TP53 is considered as a hallmark of a¯atoxin B1 contamination (Bressac et al., 1991) . Higher LOH and p53 mutation rates, and lower incidence of b-catenin mutations have been evidenced in hepatitis B virusrelated tumors (Hsu et al., 2000; Legoix et al., 1999; Marchio et al., 2000; Sheu et al., 1999) .
Tumor-prone transgenic mice oer powerful tools for investigating the molecular mechanisms of oncogenesis. Animals with uniform genetic background are maintained in controlled environment, providing a stable and theoretically unlimited resource for analysing tumors induced by the same initial oncogenic event. Transgenic models of hepatocarcinogenesis have demonstrated the high oncogenic impact of c-Myc activation on liver cells. In previous studies, we have shown that liver expression of a woodchuck c-myc transgene controlled by hepatitis virus sequences in WHV/c-myc transgenic mice induces hepatocellular adenomas and HCCs within 8 ± 12 months, with a high (near 100%) penetrance (Etiemble et al., 1994) . In this model, c-Myc is transiently overexpressed in the liver after birth, and it is re-expressed together with IGF-II at tumor onset (Liu et al., 1997) . Activation of the Wnt pathway has been implicated in a subset of these tumors by the ®nding of frequent b-catenin mutations (de La Coste et al., 1998) , but other secondary genetic events that cooperate with Myc remain poorly de®ned.
In this study, we performed a genome-wide screen of LOH in 37 tumors (27 HCCs and 10 adenomas) of C57BL/6 x Mus Musculus Castaneus F1 hybrids derived from WHV/c-myc transgenic mice. In 10 selected tumors, we further analysed DNA ploidy by¯ow cytometry and chromosome imbalances by CGH. In addition, we compared the pro®les of genetic alterations in tumors carrying mutated or wild-type bcatenin alleles. Our data, showing nonrandom losses on regions of chromosomes 4 and 14 that are homologous to frequently involved regions in human HCCs, imply that TSGs located on these chromosomes are selectively inactivated in Myc-related liver tumorigenesis.
Results
Liver tumorigenesis in hybrid C57BL/6 x Cast/ei transgenic mice
We have shown previously that liver-speci®c expression of c-Myc in WHV/c-myc transgenic mice is associated with the invariable development of liver tumors (hepatocellular adenomas and HCCs) at 8 ± 12 months of age (Etiemble et al., 1994) . The transgenic founder 93-7 (hybrid C57Bl/6 x SJL/J background) and progeny were serially backcrossed to the C57BL/6 strain for 18 generations. The resulting animals developed liver tumors in all cases within 6 ± 24 months (mean latency period: 12 months). For the present study, male and female transgenic mice were crossed with Cast/ei mice to produce F1 ospring harboring a high rate of polymorphism in microsatellite marker loci. The onset of liver tumors was markedly delayed in F1 animals compared to pure-strain C57BL/6 mice, with 80% of the F1 transgenic cohort harboring liver tumors between 12 ± 24 months (average: 16.5 months). At autopsy, most animals carried several tumor masses, with average three macroscopic nodules, often localized in the right liver lobe. At histopathological examination, the tumors consisted mainly of well-dierentiated, trabecular-type HCCs with frequent necrosis, or hepatocellular adenomas. These tumors were indistinguishable from those of the parental C57Bl/6 mice (Etiemble et al., 1994) , and adjacent liver similarly carried dysplastic lesions of varying severity (data not shown).
Genome-wide screen of LOH in liver tumors
We initially genotyped 81 tumor samples collected from 30 mouse livers by microsatellite marker analysis, using 99 markers distributed along all 19 autosomes and X chromosome. Dierent tumor samples from a given mouse that showed identical LOH patterns were considered as the same tumor, while they were regarded as independent tumors when presenting dierent LOH patterns. Finally, 37 independent tumors (27 HCCs and 10 adenomas) were included in this study. Among HCCs, 24 were well dierentiated, and three were moderately or poorly dierentiated. LOH was assessed with at least three widely spaced markers per chromosome, spanning a total distance of 1075 cM and covering 75% of the mouse genome. Because some regions of mouse chromosomes 1, 4, 8 and 14 are homologous to frequently altered chromosomal loci in human HCC (Boige et al., 1997; Nagai et al., 1997) , these chromosomes were analysed with a higher density of markers. We also positioned markers nearby 10 known TSGs, including the metastasis-suppressing gene KAI1/CD82, Wilms' tumor (WT1), cyclin-dependent kinase inhibitors INK4a/ARF and INK4b, Modi®er of Min-1 (Mom-1), breast cancer susceptibility BRCA2, ataxiatelangiectasia-mutated (ATM), mutL homologue (MLH1), TP53, retinoblastoma (RB), adenomatous polyposis coli (APC), dual speci®city phosphatase PTEN (MMAC1/ TEP1) and Myc-antagonist (Mxi1) genes. Based on reconstruction experiments, LOH was judged by reduction of allelic intensity of more than twofold, as illustrated in Figure 1 . All makers detected one or two alleles with the same size in tumor and matched nontumor samples. Therefore, in the absence of replication error on short repeat sequences, these tumors did not exhibit microsatellite instability (MIN).
LOH was detected at one or more chromosomal loci in 30/37 tumors (81%). The number of chromosomes with LOH varied from 0 ± 4 per tumor (average: 1.3) (Figure 2 ). The fractional allelic loss or FAL (fraction of chromo- Figure 1 Examples of microsatellite analysis of liver and tumor DNAs. PCR products were separated on agarose gels and stained with ethidium bromide. (a) Liver DNA from a normal F1 hybrid (NF1) was ampli®ed with D4Mit52 primers and PCR products were compared to those from Cast/ei and C57B1/6 DNAs mixed in dierent ratios. (b) Typical examples of allelic imbalances at markers D4Mit52, D14Mit84 and D1Mit486 in liver tumors somes with LOH over the total chromosomes tested) varied from 0 to 0.108 with mean value of 0.066 (+0,032, 99% con®dence interval). Average FAL indexes were slightly elevated in HCCs compared to adenomas (average: 0.070 versus 0.055) without reaching statistical signi®cance. The incidence of LOH at each of the 20 chromosomes tested ranged from 0 to 21.6% (Figure 3) . While chromosomes 13, 15 and X remained unaected in all tumors, signi®cant LOH was seen at chromosomes 1, 4, 9 and 14 (P50.01), with higher frequency at chromosome 4 (Table 1) . Interestingly, allelic imbalances at both chromosomes 4 and 14 were not seen in the same tumors. LOH at chromosome 4 was observed in both adenomas (3/10 cases) and HCCs (5/27 cases), while chromosomes 1 and 14 were aected only in HCCs. In 40% of cases, allelic loss was demonstrated at all markers along a chromosome, suggesting a high incidence of nondisjunction, but we observed more frequently interstitial LOH on dierent chromosomes. A critical region was mapped on chromosome 4, at markers D4MP15 and D4Mit117 located on each side of the INK4A/ARF locus ( Figure 4a ). Regional LOH was also observed on chromosome 14 at markers D14Mit84 to D14Mit224, an area spanning both the RB locus and a region homologous to human chromosome 8p21 ± 23 ( Figure  4b ). Other TSG-associated markers revealed no LOH rate above average on the corresponding chromosome; notably, allelic imbalance at the TP53 locus on chromosome 11 was found only in a unique tumor (Table 2) . Although tumor onset in F1 mice was markedly delayed compared to that of C57Bl/6 mice, preferential loss of the Cast/ei allele was seen only for chromosomes 1 and 19, and the Bl/6 allele of chromosome 14 was predominantly deleted. Finally, parental-speci®c allelic deletion suggesting inactivation of an imprinted TSG was not found in these tumors.
b-catenin mutations in HCCs
In previous studies, frequent somatic mutations or deletions in the N-terminal region of b-catenin have been detected in HCCs from WHV/c-myc transgenic mice (de La Coste et al., 1998) . In the present work, we found bcatenin mutations in three HCCs from F1 hybrids, including one GAT to GTT transversion at codon 32 (Asp to Gly), one GGA to GAA transition at codon 34 (Gly to Glu), and one ACC to TGC two-base transversion at codon 41 (Thr to Cys). These residues are frequently mutated in mouse and human HCCs (de La Coste et al., 1998) . In contrast with our previous report, interstitial deletions were not observed in this panel. This marked dierence might re¯ect either mouse strain speci®city or a bias due to the limited number of tumors studied.
Comparison of the LOH patterns between tumors carrying mutated and wild-type b-catenin alleles revealed that b-catenin mutation tendered to cluster with LOH at chromosome 4, but this association did not reach statistical signi®cance.
Flow cytometry analysis of DNA ploidy DNA ploidy was analysed by¯ow cytometry in a subset of 10 representative liver tumors (eight HCCs and two adenomas). Only one tumor (C690) had no LOH detected at any marker. Control analysis of normal F1 livers showed about 80% of diploid and 20% of tetraploid cells, but aneuploid hepatocytes were not found (data not shown). In most tumors, aneuploid cell populations were predominant (Table 3 ). In four hyperdiploid tumors, the diploid population represented less than 18%, likely re¯ecting contamination by normal cells. All other cases showed a higher percentage of diploid cells (32.5 ± 61.5%), suggesting that a signi®cant fraction of tumor cells remained diploid. Aneuploid populations consisted either of hyperdiploid or hypertetraploid cells, and three tumors demonstrated mixed aneuploid populations with two dierent DIs (Table 3) .
CGH analysis of chromosome imbalance
We next analysed these 10 tumors with known ploidy by CGH. Typical examples of the experimental data are presented in Figure 5 . Chromosomal imbalances were found in all cases, including a tumor showing no abnormality by microsatellite analysis. Most CGH pro®les exhibited both DNA copy gains and losses at dierent chromosomal regions, but one tumor had only gains and three had only losses (Table 3) . DNA losses prevailed over gains in most tumors (average values: 3.1 losses versus 1.7 gains per tumor). Interestingly, tumors carrying a b-catenin mutation had more gains and fewer losses than the others (P50.01). DNA gains, usually on the entire chromosome, were seen at chromosomes 16 (four tumors), 19 (three tumors), and at chromosomes 1, 3, 15 and 18 in two cases (Figure 6 ). Overrepresentation of chromosome 1 was observed in tumors carrying a b-catenin mutation (Table 3) . High level ampli®cation of a limited chromosomal region was never observed.
Complete or regional losses were frequent at chromosomes 14 (eight cases) and 4 (seven cases), with common regional losses at bands 4 C3 ± C6, 4 D1 ± E1 and 14 D (Figure 6 ). Recurrent losses occurred also at chromosomes 10 (three cases), 7 and 8 (two cases), but curiously, chromosome 9 remained apparently unaltered in all tumors. Complex abnormalities were not common and only seen on chromosome 3 in a unique case (Table 3) .
The frequency of numerical chromosome imbalances revealed by CGH was signi®cantly higher than LOH frequency in the tumors analysed (P50.01), in agreement with previous observations in human HCC (Marchio et al., 1997) . Tumor C690 is an extreme case in which no LOH was detected, but losses involved ®ve chromosomes in CGH analysis. These dierences may re¯ect dierent types of abnormalities measured by Table 3) CGH and microsatellite analysis. In aneuploid tumors, CGH may reveal gains or losses that restore the ratios of paternal to maternal alleles on the corresponding chromosome, and LOH cannot be detected in these regions. However, LOH at chromosomes 3, 4, 8, 14 and 17, including total or regional loss was seen as chromosome loss by CGH in all cases (Table 3 ). In particular, LOHs at chromosomes 4 and 14 in ®ve tumors were nicely con®rmed as losses by CGH (see Figure 4 ). In contrast, allelic imbalance at chromosomes 1 and 19 correlated with gain by CGH. Similarly in human HCC, LOH at dierent chromosome arms was generally correlated with DNA copy number losses by CGH, with few exceptions including 1q, which is homologous to mouse chromosome 1 (Buendia, 2000; Laurent-Puig et al., 2001) . Thus, despite frank divergence in tumors C471 and C690, there was a general agreement between data generated by the two techniques. In addition, our CGH analysis revealed recurrent gains on chromosomes 16, which had not been reported so far, while chromosomal gains on chromosomes 15 and 19 have been detected by conventional cytogenetic analysis in carcinogen-induced liver tumors (Ogawa et al., 1999) .
Discussion
We have shown here that murine liver tumors induced by targeted expression of c-Myc display major, nonrandom allelic losses on chromosomes 4 and 14. Myc activity in cell transformation has been related to its ability to trigger proliferation and genetic instability (Felsher and Bishop, 1999; Pelengaris et al., 2000) . Accordingly, all WHV/ c-myc tumors analysed by CGH displayed numerical chromosomal changes, and most of them harbored complex diploid/aneuploid patterns indicating mosaic cell populations with dierent DNA content. In the absence of microsatellite instability (MIN) revealed by polymorphic marker analysis, our CGH data provide evidence for moderate chromosomal instability (CIN) in Myc-induced liver tumors. LOH is considered as a ratelimiting event in tumorigenesis, and in some cases, it might represent the ®rst hit in the biallelic inactivation of tumor suppressor genes (Luttges et al., 2001 ). However, we found a low incidence of LOH throughout the genome, a feature also reported in a variety of murine cancers (Davis et al., 1994; Dietrich et al., 1994; Hegi et al., 1994; Lander and Fan, 1997) . Because LOH studies can be carried out only in F1 hybrids of evolutionary Only markers with LOH values above 9.87% (99% con®dence interval of loci ampli®ed) are shown. The highest LOH rates are denoted by an asterisk (P50.01) distant strains, low LOH rates might re¯ect the inhibitory eect of divergent chromosomal sequences on mitotic recombination (Shao et al., 2001) . Such a mechanism could be involved in increased tumor resistance of F1 hybrids compared to C57Bl/6 inbred strain, although involvement of modi®er loci cannot be excluded. In this context, our allelotype study indicates that inactivation of tumor suppressor genes on chromosomes 4 and 14 might play a crucial role in Myc-induced tumorigenesis.
A critical region showing frequent LOH was located on chromosome 4 between 42.6 cM and 44.5 cM (band C4 ± C7). Allelic losses in the homologous region on human chromosome 9p21 have been found in about (Sargent et al., 1999) . In other murine cancers, including lung and mammary tumors, frequent allelic losses have been detected in this chromosomal region (Hegi et al., 1994; Herzog et al., 1994; Ritland et al., 1997) . In contrast, LOH at chromosome 4 was not recorded in spontaneous and chemically induced liver tumors of B6C3 mice, in which the overall allelotype pattern was clearly dierent, suggesting distinct pathways of hepatocarcinogenesis (Davis et al., 1994) . The candidate region on chromosome 4 contains three tumor suppressor genes, p15 INK4B , p16 INK4A and p19 ARF . The INK4 proteins bind and inhibit cyclin-dependent kinases CDK4 and CDK6, thereby inhibiting their interaction with D-type cyclins and consequent phosphorylation of RB and related proteins. P16
INK4A (CDKN2A/MST1) is frequently inactivated by homozygous deletions or hypermethylation of the promoter region in a variety of neoplasms (Serrano, 2000) . In about one half of human HCCs, extensive CpG methylation of the p16 promoter was correlated with downregulated expression of the protein (Liew et al., 1999; Matsuda et al., 1999) . The product of the alternative reading frame of the INK4a locus, p19 ARF (p14 ARF in humans) activates the p53 pathway by inhibiting functions of Mdm2, and it might also induce growth arrest independently of p53 (Duro et al., 1995; Eymin et al., 2001; Quelle et al., 1995; Weber et al., 1999 Weber et al., , 2000 . P19
ARF is activated by c-Myc, and disruption of the ARF/ p53 pathway plays a crucial role in Myc-induced lymphomagenesis (Eischen et al., 1999; Sherr and Weber, 2000) . Moreover, engineered alterations of the INK4a/ARF locus have suggested that p19 ARF might be more relevant than p16
INK4A for tumor suppression in mice (Serrano, 2000) . A second locus harboring signi®cant LOH rates and regional losses by CGH is located on the distal part of chromosome 4. This region has been implicated in intestinal tumor resistance in mice carrying inactive Min-1 alleles. It is homologous with human chromosome 1p32 ± 36 that is frequently altered in human HCCs.
The second chromosome showing recurrent LOH and DNA losses in WHV/c-myc mice is chromosome 14, with interstitial deletions between 30.6 and 42.0 cM (band D ± E1). Homologous sequences on human chromosome arms 8p21 ± 23 and 13q14 are frequently deleted in liver tumors (Marchio et al., 1997; Nagai et al., 1997) . While no candidate gene for HCC has been localized so far on 8p, the RB gene at 13q14 is frequently downregulated in human liver cancer, via allelic deletions, silencing of p16 INK4A or direct interaction with gankyrin leading to degradation by the proteasome (Higashitsuji et al., 2000; reviewed in Buendia, 2000) . Our CGH data are in agreement with previous studies of liver tumors from c-myc/TGF-a mice, demonstrating recurrent cytogenetic alterations of chromosome 14, with frequent involvement of band 14E1 (Sargent et al., 1999) . Evidence for disruption of the RB/E2F pathway in these tumors has been reported (Santoni-Rugiu et al., 1998) . Further genetic and expression studies of INK4A, INK4B, ARF and RB in these tumors will provide critical information on the importance of these genes in Myc-induced hepatocarcinogenesis. By contrast, we did not ®nd any interstitial deletion in other TSG loci investigated. Although recent data have demonstrated a synergistic cooperation between Myc and p53 in liver tumorigenesis (Renard et al., 2000) , LOH at the TP53 locus was seen here in a unique case, and numerical alterations were not detected on chromosome 11 by CGH, in agreement with cytogenetic analysis of c-myc/TGF-a tumors (Sargent et al., 1999) .
In conclusion, comprehensive allelotyping combined with molecular cytogenetic technology has led to de®ne major genetic changes in murine liver tumors. This study represents a ®rst step towards the identi®cation of tumor suppressor networks that cooperate with c-Myc in liver cell transformation. It has been shown that loss of INK4A/ARF promotes lymphoma harboring apoptotic defects and increased chemoresistance (Schmitt et al., 1999) . The WHV/c-myc transgenic model might therefore be useful for testing therapeutic strategies to counteract the selective disruption of tumor suppressor pathways in liver tumorigenesis.
Materials and methods

Transgenic mice and tumor samples
The WHV/c-myc transgenic mice have been described previously (Etiemble et al., 1994) . Male and female transgenic mice in the C57BL/6 strain were crossed with M. musculus castaneus Ei (Cast/ei) mice. Transgenic (B16 x Cast/ei) F1 ospring were identi®ed by hybridization of tail DNA with a WHV DNA probe. Mice were examined at weekly interval for up to 24 months and euthanized when presenting with abdominal broadening. All animals were maintained in a pathogen-free facility and handled according to the guidelines of the MinisteÁ re de l'Agriculture et de la PeÃ che (France).
Tumor samples and adjacent liver tissues were ®xed in 4% paraformaldehyde and embedded in paran for histopathological examination. For nucleic acid analysis, tumor samples were dissected free of adjacent liver tissues, capsule and necrosis, snap-frozen in liquid nitrogen and kept at 7808C. Livers from nontransgenic C57BL/6, Cast/ei, and F1 hybrid mice were used as normal controls. DNA was isolated by standard proteinase K digestion and phenol extraction.
Microsatellite marker selection and PCR amplification
The selection of microsatellite markers for genome-wide scan was based on their linkage position and on size dierence 420 bp between the BL/6 and Cast/ei alleles, as described in the MIT database and the Mouse Genome Database of Jackson Laboratory. The complete list of markers used in this study is available upon request. Genomic DNA (20 ng) was ampli®ed by PCR as described (Nagai et al., 1997) , and PCR products were analysed by electrophoresis through 3.5% or 4% Neusive 3 : 1 agarose gels followed by ethidium bromide staining. Several markers for which BL/6 and Cast/ ei alleles diered by less than 20 bp were analysed by PCR ampli®cation with a-32 P dCTP (3000 Ci/mol) and electrophoresis through 6 or 7% denaturing polyacrylamide gels as described (Nagai et al., 1997) .
LOH analysis
LOH in tumor DNA was evaluated by comparison with the mean of 10 DNAs from normal F1 mice. LOH was judged by a reduction 450% in signal intensity of one allele. The data were con®rmed by repeated analysis of several DNA samples from the same tumor in two or three independent PCR experiments. Signal intensities were quanti®ed by Syngene Photo Image System (Syngene, Cambridge, UK).
Mutational analysis of b-catenin
The N-terminal region of the b-catenin gene (exon 1 to exon 3) was ampli®ed by PCR from tumor and paired non-tumor DNA as described (Tran van Nhieu et al., 1999) . The PCR products were either directly sequenced or cloned in the pCR2.1 TOPO vector (Invitrogen, Groningen, The Netherlands). Exon 2 was sequenced with the forward primer 5'-TGATGGAGTTGGA-CATGGCCATG-3' and reverse primer 5'-CCCACTCATA-CAGGACTTTGGGAGG-3', by using T7 Sequenase sequencing kit (USB-Amersham, Cleveland, OH, USA).
DNA flow cytometry
Frozen tumor tissues (1 ± 2 mm 3 ) were suspended in 300 ml PBS-Tween and stained with propidium iodide. Samples were analysed on a FAC SORT¯ow cytometer (Becton Dickinson, San Jose, CA, USA) equipped with a 15 MW air-cooled 488-nm argon-ion laser. Tumor cell populations with DNA index (DI)=1 were de®ned as diploid and DI=2 as tetraploid. Tumors with intermediate DI values in 410% cells were considered as aneuploid.
CGH and digital image analysis
CGH experiments were performed according to previously described protocols with some modi®cations (Kallioniemi et al., 1994; Shi et al., 1997) . Tumor DNA was labeled with uorescein-12-dUTP and normal reference DNA with Texas Red-5-dUTP (NEN Life Sciences, Boston, MA, USA) by nick translation. Each tumor DNA was competitively hybridized with normal reference DNA prepared from mice of the other sex. Equal amounts (500 ng) of labeled tumor and reference DNAs were co-precipitated with 10 mg of mouse Cot-I DNA (Gibco Life Technologies, Gaithersburg, MD, USA), denatured at 708C for 10 min, and incubated at 378C for 2 h. Metaphase cell preparations obtained from neonatal ®broblasts were denatured in 70% formamide/2x SSC at 708C for 2 min, and incubated with the probes in a humid chamber at 378C for 3 days. Slides were washed and counterstained with 4,6-diamino-2-phenylindole (DAPI) in anti-fade solution. Digital images of the three¯uorochromes were acquired using a computer-driven cooled CCD color camera mounted on a Leitz¯uorescence microscope (Leica, Wetzlar, Germany). Mouse chromosomes were stained with Dapi and identi®ed by computer-generated reverse Dapi banding. Quips Software (Vysis Inc, Downers Grove, IL, USA) was used for analysis of digital images and determination of ratio pro®les of¯uorescence intensity along chromosomes. Average ratio pro®les were calculated after analysis of 10 ± 15 representative metaphase spreads. As preliminary test for evaluating the quality of hybridization, we veri®ed correct 2 : 1 labeling ratio of X chromosome. This chromosome was therefore excluded from CGH analysis. All juxtacentromeric loci and regions rich in heterochromatin in chromosomes 1 (band D, E1 ± 2), 4 (band E2), 10 (band A4), 12 (band B), 13 (band B, C1) and 14 (band A3, B) that could not be completely blocked by Cot-1 DNA were excluded from data interpretation. Pro®les were then normalized to an average value of 0.95 for the entire genome, according to control experiments. The normal pro®le ranges were de®ned as mean ratio deviation (95% con®dence interval) between 0.82 and 1.08 for pseudo diploid hyperdiploid tumors, and 0.85 ± 1.05 for tetraploid or polyploid tumors. Losses and gains were considered when observed in at least 50% of pro®les.
Statistical analysis
LOH frequencies at individual chromosomes and background rate of LOH were compared by two-tailed Student's t-test analysis. The dierence was considered signi®cant at P value 50.01. Association of strain bias and parental imprinting with LOH and between group comparisons for LOH frequency was analysed by w 2 -test.
